CRISPR lung treatment offers hope for cystic fibrosis.

A recent study has shown that a lung-targeted CRISPR gene-editing therapy has the potential to be an effective and long-lasting treatment for cystic fibrosis. The therapy successfully edited DNA in hard-to-reach lung stem cells in mice, with the modifications lasting for at least 22 months. The researchers used lipid nanoparticles to deliver the gene-editing components to the lungs, overcoming the challenge of getting therapeutic agents past the mucus and other defenses in the lungs. If approved for human trials, this therapy could significantly improve lung function in people with cystic fibrosis. [Extracted from the article]